Literature DB >> 7353074

Cetiedil: its potential usefulness in sickle cell disease.

L J Benjamin, G Kokkini, C M Peterson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7353074

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  5 in total

1.  Oxpentifylline and cetiedil citrate improve deformability of dehydrated sickle cells.

Authors:  J Stuart; P C Stone; Y Y Bilto; A J Keidan
Journal:  J Clin Pathol       Date:  1987-10       Impact factor: 3.411

2.  Bepridil and cetiedil. Vasodilators which inhibit Ca2+-dependent calmodulin interactions with erythrocyte membranes.

Authors:  P Agre; D Virshup; V Bennett
Journal:  J Clin Invest       Date:  1984-09       Impact factor: 14.808

3.  Effect of cetiedil on cation and water movements in erythrocytes.

Authors:  W F Schmidt; T Asakura; E Schwartz
Journal:  J Clin Invest       Date:  1982-03       Impact factor: 14.808

4.  Potential use of biaromatic L-phenylalanyl derivatives as therapeutic agents in the treatment of sickle cell disease.

Authors:  J R Votano; J Altman; M Wilchek; M Gorecki; A Rich
Journal:  Proc Natl Acad Sci U S A       Date:  1984-05       Impact factor: 11.205

5.  Effect of cetiedil, an in vitro antisickling agent, on erythrocyte membrane cation permeability.

Authors:  L R Berkowitz; E P Orringer
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.